MYMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MYMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. MyMD Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. MyMD Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ -2.79 Mil. MyMD Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. MyMD Pharmaceuticals has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical data trend for MyMD Pharmaceuticals's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MyMD Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Interest Expense | -1.19 | -0.61 | - | - |
MyMD Pharmaceuticals Quarterly Data | ||||||||||||||||
Mar20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Interest Expense | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MyMD Pharmaceuticals (NAS:MYMD) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
MyMD Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-2.79 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.00 Mil.
MyMD Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
MyMD Pharmaceuticals had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. MyMD Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.
Paul Rivard | officer: EVP of Operations, GC | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Caroline C Williams | 10 percent owner | 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
Adam Kaplin | officer: Chief Scientific Officer | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Jude Uzonwanne | director | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Craig Eagle | director | POST OFFICE BOX 4590, NEW YORK NY 10163 |
Chapman Christopher C Jr | director, officer: President, Chief Med. Officer | C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814 |
Ian Rhodes | officer: Interim CFO | 1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824 |
Stuart M Benson | officer: Chief Financial Officer | EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118 |
Hudson Bay Capital Management Lp | 10 percent owner | 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Sander Gerber | 10 percent owner | C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Robert C Schroeder | director | 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724 |
Howard Yeaton | officer: CEO, CFO | 79 LLOYD ROAD, HOHOKUS NJ 07423 |
Tarbox Richard C Iii | director | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
Christopher C Schreiber | director | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
From GuruFocus
By PRNewswire PRNewswire • 12-16-2021
By Business Wire Business Wire • 04-12-2023
By Business Wire Business Wire • 08-03-2022
By Business Wire Business Wire • 07-26-2022
By Business Wire • 08-02-2023
By Business Wire • 12-06-2023
By Business Wire Business Wire • 06-21-2022
By ACCESSWIRE • 12-29-2023
By Business Wire Business Wire • 07-12-2022
By Business Wire Business Wire • 11-17-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.